Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Balaguer V, Albayaty M, Jimenez E, Wählby-Hamrén U, Astbury C, Seoane B, Malice MP, Lei A, Aggarwal A, Psallidas I. Balaguer V, et al. Among authors: astbury c. Respir Res. 2020 Sep 9;21(Suppl 1):212. doi: 10.1186/s12931-020-01474-1. Respir Res. 2020. PMID: 32907575 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Jimenez E, Astbury C, Albayaty M, Wählby-Hamrén U, Seoane B, Villarroel C, Pujol H, Bermejo MJ, Aggarwal A, Psallidas I. Jimenez E, et al. Among authors: astbury c. Respir Res. 2020 Sep 9;21(Suppl 1):211. doi: 10.1186/s12931-020-01470-5. Respir Res. 2020. PMID: 32907576 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D, Balaguer V, Astbury C, Wählby-Hamrén U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Singh D, et al. Among authors: astbury c. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7. Respir Res. 2020. PMID: 32907566 Free PMC article. Clinical Trial.
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
Singh D, Beier J, Astbury C, Belvisi MG, Da Silva CA, Jauhiainen A, Jimenez E, Lei A, Necander S, Smith JA, Wählby Hamrén U, Xin W, Psallidas I. Singh D, et al. Among authors: astbury c. Eur Respir J. 2022 Apr 7;59(4):2100972. doi: 10.1183/13993003.00972-2021. Print 2022 Apr. Eur Respir J. 2022. PMID: 34503985 Free PMC article. Clinical Trial.
Human nocturnal blood melatonin and liver acetylation status.
Smith JA, Helliwell PS, Isdale A, Astbury C, Padwick DJ, Bird HA. Smith JA, et al. Among authors: astbury c. J Pineal Res. 1991 Jan;10(1):14-7. doi: 10.1111/j.1600-079x.1991.tb00004.x. J Pineal Res. 1991. PMID: 2056426
106 results